CEL-SCI FY2025 EPS Forecast Increased by Zacks Small Cap

CEL-SCI Co. (NYSE:CVM) – Investment analysts at Zacks Small Cap lifted their FY2025 earnings per share (EPS) estimates for shares of CEL-SCI in a report released on Monday, February 10th. Zacks Small Cap analyst J. Vandermosten now anticipates that the company will post earnings per share of ($0.29) for the year, up from their previous estimate of ($0.38). The consensus estimate for CEL-SCI’s current full-year earnings is ($0.38) per share. Zacks Small Cap also issued estimates for CEL-SCI’s FY2026 earnings at ($0.18) EPS.

Separately, StockNews.com assumed coverage on shares of CEL-SCI in a research note on Sunday. They set a “sell” rating on the stock.

CEL-SCI Stock Up 3.9 %

CEL-SCI stock opened at $0.37 on Wednesday. The business’s 50-day moving average price is $0.49 and its 200 day moving average price is $0.81. The company has a quick ratio of 1.09, a current ratio of 1.31 and a debt-to-equity ratio of 0.62. The firm has a market cap of $27.68 million, a price-to-earnings ratio of -0.73 and a beta of 0.69. CEL-SCI has a 52 week low of $0.33 and a 52 week high of $2.50.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Calton & Associates Inc. acquired a new stake in shares of CEL-SCI during the 3rd quarter valued at about $50,000. Plotkin Financial Advisors LLC acquired a new stake in CEL-SCI in the third quarter valued at approximately $98,000. Finally, Geode Capital Management LLC grew its holdings in CEL-SCI by 9.6% in the third quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock valued at $650,000 after purchasing an additional 53,879 shares during the period. Institutional investors and hedge funds own 12.08% of the company’s stock.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.